Agency IQ

JUNE 2, 2023

What We Expect the FDA to do in June 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 52

FDA Science Licensing Licensing 52

FDA Law Blog: Biosimilars

JANUARY 11, 2024

This day-long (FREE) seminar is a must-attend event for anyone in the pharmaceutical sector interested in understanding the “ins and outs” of doing business in the Territory, as well as an opportunity to interact with those who already have a keen understanding of doing business in Puerto Rico. HPM is a co-sponsor of the event.

Pharmaceuticals 57

Pharmaceuticals Compliance Licensing Licensing 57

The Pharma Data

MARCH 30, 2021

Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. You should not place undue reliance on these statements. Source link:[link].

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec. Biohaven Forward-looking statements.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

AUGUST 17, 2020

The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities. Readers should not place undue reliance on forward-looking statements.

Science 40

Science Production Licensing Licensing 40

Advarra

APRIL 30, 2024

For example, non-medical personnel should not assess adverse event causality or confirm the clinical significance of lab results. A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. Both the medical licenses and nurse licenses need to be up to date.

Licensing 52

Licensing Licensing Pharmacy FDA 52

The Pharma Data

JUNE 30, 2021

With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p <0.0001). Event-free survival is defined as time from randomization to disease progression, commencement of new lymphoma therapy, or death from any cause. This press release features multimedia.

Therapies 52

Therapies Treatment Virus Vaccine 52

The Pharma Data

DECEMBER 13, 2020

In the event of regulatory approval of both RLY-1971 and GDC-6036 in combination, Relay Therapeutics is eligible to receive additional royalties. Relay Therapeutics retains the right to combine RLY-1971 with its selective FGFR2 and mutant-selective PI3K?

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., VICTORIA, British Columbia & ROCKVILLE, Md.–( –( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. Also, many of the factors are beyond our control.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 1 Kratz et al.,

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Perficient: Drug Development

AUGUST 12, 2024

Comprehensive and Unified Offering Azure Integration Services offers a comprehensive and unified suite of integration tools, including Azure Logic Apps, Azure Service Bus, Azure API Management, and Azure Event Grid. Businesses pay only for the resources they use, allowing for better cost control and budgeting.

Compliance 105

Compliance Licensing Licensing Production 105

FDA Law Blog: Biosimilars

JUNE 12, 2024

With input from medical professionals, stakeholder, trade associations, and patient advocacy groups, FDA provided a pathway to market for air-conduction hearing aids without a prescription or the involvement of a licensed professional. FDA does, however, expect to issue a report on OTC hearing aid adverse events to Congress by August 2024.

FDA 109

FDA Regulations Treatment Licensing 109

Perficient: Drug Development

MARCH 5, 2024

Assigning the Right License Access to objects is determined based on the license type, such as High-Volume Customer Community, Customer Community Plus, and Partner Community. Regularly Run Security Scans Tools like Salesforce event monitoring, IBM Qradar, and CheckMarx can conduct regular health scans.

Licensing 59

Licensing Licensing International Regulations 59

FDA Law Blog: Biosimilars

AUGUST 29, 2024

Each party that violates or assists in the violation of this section shall forfeit and pay to the United States a civil penalty sufficient to deter violations of this section, but in no event greater than 3 times the value received by the party that is reasonably attributable to the violation of this section.

Biosimilars 57

Biosimilars Licensing Licensing Production 57

The Pharma Data

NOVEMBER 29, 2020

Compared to conventional “occupancy-driven” pharmacological modality, the “event-driven” PROTAC technology has many advantages, such as high potency, high selectivity, with catalytic mode of action, and the ability to target undruggable proteins.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

MARCH 14, 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines.

Vaccine 52

Vaccine Virus Licensing Licensing 52

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 80

Laboratories FDA Regulations Licensing 80

Perficient: Drug Development

SEPTEMBER 19, 2023

Last week, Perficient attended the largest AI event in the world, Dreamforce, in San Francisco. jobs by 2028.

Licensing 59

Licensing Licensing Production Marketing 59

Drug Patent Watch

OCTOBER 29, 2019

This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. Abstract The key events in the….

Licensing 41

Licensing Licensing Drugs 41

Perficient: Drug Development

NOVEMBER 28, 2023

Hexagonal Architecture and DevSecOps: Fundamentals of our operation The state-of-the-art of our ecosystem is defined by a hexagonal architecture , domain-driven design, and event-driven architecture. In the vehicular domain, our systems, connected to the Azure cloud via IoT, search for incident-related license plates in real time.

Licensing 52

Licensing Licensing Government Production 52

The Pharma Data

DECEMBER 21, 2020

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

JANUARY 4, 2021

The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. The event reported today has no immediate impact on the consolidated financial results for the accounting period ending December 2021. ” About the License Agreement. TOKYO and CAMBRIDGE, England , Jan. Source link.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

The Pharma Data

AUGUST 15, 2021

6,9,10 Clinical studies demonstrated that TICOVAC was generally well-tolerated with no unexpected adverse events or vaccine-related serious adverse events observed. In clinical trials, the safety and immunogenicity of TICOVAC were assessed across two age groups (1-15 years of age and >16 years of age). in 1-15 year olds and 98.7-100%

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

The Pharma Data

APRIL 27, 2023

The most frequently observed solicited adverse events were injection site pain, fatigue, myalgia, headache, and arthralgia. The most frequently observed solicited adverse events were injection site pain, fatigue, myalgia, and headache. Efficacy was 94.6% (95% CI, 65.9–99.9, These were generally mild to moderate and transient.

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

SEPTEMBER 25, 2020

Furthermore, the drug’s safety profile was shown to be in line with previous findings, with a similar prevalence of adverse events. Gilead’s Japanese branch will hold the commercial license as well as handle supply of the product in Japan, while Eisai will be responsible for distributing it in the country for RA. “RA

Licensing 40

Licensing Licensing International Treatment 40

The Pharma Data

JANUARY 14, 2021

Before today’s announcement, physicians wishing to prescribe buprenorphine outside of opioid treatment programs had to take an eight-hour course and often waited 60 to 90 days to receive the waiver once the course is completed and the license application is submitted.

Treatment 52

Treatment Licensing Licensing Hospitals 52

LifeSciVC

APRIL 24, 2024

If adverse events are anticipated, it is important to understand gene dosage for such an effect (e.g., Alternatively, are there potential existing assets that may be available for in-licensing, especially if the potential licensor has pivoted strategic directions (i.e., asset has not been de-prioritized due to safety or efficacy)?

Production 114

Production Small Molecule Regulations Trials 114

FDA Law Blog: Biosimilars

JULY 5, 2023

Under section 503B, drugs compounded by an FDA-registered outsourcing facility under the supervision of a licensed pharmacist can qualify for exemptions from FDA approval, labeling with adequate directions for use, and certain drug supply chain security requirements, subject to specific conditions. Draft Guidance III.B.2(e)

FDA 52

FDA FDA Approval Licensing Licensing 52

The Pharma Data

NOVEMBER 9, 2021

Among those treated with OLUMIANT, the overall prevalence rate of adverse events per 100 patient times of exposure was22.6, and the prevalence rate of serious adverse events was7.4. Priority check events included herpes zoster (3, n = 100), liver dysfunction (3, n = 100), serious infection (1.5, times and a outside exposure of9.3

Treatment 52

Treatment FDA Approval Licensing Licensing 52

The Pharma Data

APRIL 26, 2022

To date, Veklury and generic remdesivir have been made available to more than 11 million patients around the world, including more than 7 million people in 127 middle- and low-income countries through Gilead’s voluntary licensing program. About Gilead Sciences. Gilead Sciences, Inc.

Treatment 52

Treatment Hospitals Science Licensing 52

The Pharma Data

OCTOBER 20, 2020

We look forward to successful commercialization and licensing of TLC’s programs across the globe under Mr. Bliss’s leadership, as well as to creating benefit and bringing value for all of TLC’s stakeholders.”. Contact Dawn Chi Corporate Communications dawn@tlcbio.com. Source link.

Licensing 40

Licensing Licensing Pharmaceutical Companies Clinical Trials 40

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. But now, we’re one step closer. Navin Varadarajan, University of Houston M.D.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

DECEMBER 13, 2020

SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events.

Science 52

Science Licensing Licensing Production 52

The Pharma Data

AUGUST 21, 2020

Virtual Event. Lilly first licensed Tyvyt from Innovent in 2015. The original deal included rights outside of China, but in 2017, Lilly licensed back those rights while retaining downstream economics, Taylor said. Six PD-1/L1 agents are already on the U.S. market, with Merck & Co.’s DEVELOP A UNIFIED SCIENTIFIC VOICE.

Licensing 52

Licensing Licensing FDA Therapies 52

The Pharma Data

JUNE 25, 2021

Preliminary analyses show similar adverse events in the placebo and treatment arms. The primary analysis was to be conducted 30 days after 25 events meeting the primary efficacy endpoint definition had occurred. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.

Trials 52

Trials Long-Term Care Facilities Virus Government 52